Stocks making the biggest moves premarket: Peloton Interactive, Roivant Sciences, Boston Scientific & more
Roivant Sciences (RVN) shares rose 24% after positive Phase 2 trial results for its pulmonary hypertension treatment. Novartis (NVS) fell 12% due to disappointing Phase 3 trial results. Peloton (PTON) dropped 4% following a Morgan Stanley downgrade. Boston Scientific (BSX) declined 2% after reporting a cyberattack impact. Bloom Energy (BE) gained 6% ahead of its S&P 500 inclusion. Quantum computing stocks rose on U.S. investment news.
How this was made
The 30-second read
Why it matters
Each disclosed event provides a distinct catalyst that can drive short‑term price action, with varying degrees of materiality.
Market read
The mix of biotech data, defense upgrades, and tech policy support creates a volatile pre‑market environment with multiple trading opportunities.
What to watch
Potential supply‑chain constraints for Bloom Energy and the longer‑term impact of Boston Scientific's cyberattack.
Background
The article aggregates the biggest pre‑market movers, highlighting fresh corporate disclosures and analyst actions.
Ticker impact
Lockheed Martin ticked 0.7% higher after UBS upgraded the stock to buy from neutral.
Modest upside in pre‑market trading.
Upgrade reflects earnings growth potential but move is modest.
Novartis fell 12% after Phase 3 results showed its del‑desiran drug failed to improve myotonic dystrophy patients.
Further downside if no remedial action is announced.
Failed Phase 3 is a material setback for a large pharma.
Peloton slid more than 4% after Morgan Stanley downgraded it to underweight.
Potential further decline if earnings miss expectations.
Analyst downgrade signals short‑term weakness.
Boston Scientific slipped >2% after reporting a cyberattack that may hit 2026 sales and profit targets.
Possible continued pressure pending impact assessment.
Operational disruption can affect guidance.
Bloom Energy rose >6% as it prepares to join the S&P 500 on Sept. 21, citing AI data‑center demand.
Likely further upside as index funds add the stock.
S&P 500 addition typically drives buying.
Market effects
Biotech trial successes and failures, defense upgrades, and quantum‑computing policy support may shift sector sentiment.
U.S. pre‑market moves could influence broader market indices.
Quantum‑computing government stakes signal global tech investment trends.
Counterpoint
Some investors may view the biotech rally as over‑optimistic without Phase 3 data; quantum stocks could be over‑priced on policy hype.
Key entities
- companyRoivant Sciences
Biotech firm reporting Phase 2 trial data.
- companyLockheed Martin
Defense contractor receiving an analyst upgrade.
- companyNovartis
Pharma company with a failed Phase 3 trial.
- companyPeloton Interactive
Fitness equipment maker downgraded by Morgan Stanley.
- companyBoston Scientific
Medical device maker reporting a cyberattack impact.
